Claims
- 1. A compound of formula ##STR22## in which R.sub.1 denotes a hydrogen atom,
- R.sub.2 denotes an aminocarbonylamino group, which may be monosubstituted, disubstituted or trisubstituted by an alkyl group having 1 to 20 carbon atoms, by an alkenyl or alkynyl group having 3 to 5 carbon atoms in each case, by a bicyclic or tricyclic alkyl group having 7 to 11 carbon atoms, by a cycloalkyl, cycloalkylalkyl, aralkyl or aryl group, wherein the substituents may be the same or different, and an alkyl group may be substituted in the 4, 5 or 6 position by a hydroxy, alkanoyl or trifluoroacetyl group,
- R.sub.3 denotes a hydrogen atom,
- an alkyl group having 1 to 6 carbon atoms, in which a methylene group may be replaced by an oxygen or sulphur atom, a sulphinyl, sulphonyl or alkylamino group, and a methyl group may be substituted by a hydroxy, alkoxy, amino, alkylamino or dialkylamino group, but wherein the methylene group next to the benzimidazole ring may not be replaced by a sulphinyl or sulphonyl group, and when a methylene group is replaced and a methyl group is substituted at the same time, they must be separated from one another by at least 2 carbon atoms,
- an alkenyl or alkynyl group each having 3 to 5 carbon atoms,
- a phenylalkyl group,
- a cycloalkyl or cycloalkylalkyl group, in which the cycloalkyl moiety may contain 5 to 7 carbon atoms in each case,
- R.sub.4 denotes a group containing a Br onsted acid or a radical which can be converted in vivo to a group containing a Br onsted acid,
- R.sub.5 denotes a hydrogen atom, and
- R.sub.6 denotes a hydrogen atom,
- the aryl group means a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a hydroxy, alkyl, alkoxy, phenylalkoxy or trifluoromethyl group, wherein the alkyl moiety may contain 1 to 4 carbon atoms in each case, or a naphthyl group,
- the cycloalkyl group means a cycloalkyl group having 3 to 7 carbon atoms, which may be substituted by one or two alkyl groups, and
- the remaining alkyl groups mentioned in the definition of the radicals R.sub.1 to R.sub.6 mean in each case alkyl groups having 1 to 3 carbon atoms,
- or a pharmaceutically acceptable salt thereof.
- 2. A compound of the formula I according to claim 1, in which R.sub.1 to R.sub.3, R.sub.5 and R.sub.6 are as defined in claim 1, and
- R.sub.4 denotes a carboxy or 1H-tetrazolyl group, an alkoxycarbonyl group having a total of 2 to 7 carbon atoms, an aralkoxycarbonyl group, a pivaloyloxymethoxycarbonyl, phthalidylmethoxycarbonyl, ethoxycarbonyloxyethoxycarbonyl, methoxymethoxycarbonyl, cyclohexyloxycarbonylmethoxycarbonyl or (1,3-dioxa-2-oxo-4-methyl-cyclopenten-5-yl)-methoxycarbonyl group.
- 3. A compound of the formula I according to claim 1, in which
- R.sub.1 denotes a hydrogen atom,
- R.sub.2 denotes an aminocarbonylamino group, which may be monosubstituted, disubstituted or trisubstituted by an alkyl group having 1 to 12 carbon atoms, by an alkenyl or alkynyl group having 3 to 5 carbon atoms in each case, by a bicyclic or tricyclic alkyl group having 7 to 11 carbon atoms, by a cycloalkyl, cycloalkylalkyl or phenylalkyl group, wherein the substituents may be the same or different, and the alkyl moiety may contain 1 to 3 carbon atoms and the cycloalkyl moiety may contain 5 to 7 carbon atoms, and an alkyl group may be substituted in the 4, 5 or 6 position by a hydroxy or trifluoroacetyl group,
- R.sub.3 denotes a hydrogen,
- a hydroxy group,
- an alkyl group having 1 to 5 carbon atoms, wherein the methyl group may be additionally substituted by a hydroxy group, by an alkoxy, alkylsulphenyl, alkylsulphinyl or alkylsulphonyl group each having 1 to 3 carbon atoms, a cycloalkyl or cycloalkylalkyl group, in which the cycloalkyl moiety may contain 5 to 7 carbon atoms and the alkyl moiety may contain 1 to 3 carbon atoms, an alkenyl or alkynyl group each having 3 to 5 carbon atoms, a phenylalkyl group having 1 to 3 carbon atoms, or
- an alkylamino group having 1 to 4 carbon atoms,
- R.sub.4 denotes an alkoxycarbonyl having a total of 2 to 5 carbon atoms, a carboxy or tetrazolyl group,
- R.sub.5 denotes a hydrogen atom, and
- R.sub.6 denotes a hydrogen atom.
- 4. A compound of the formula I according to claim 1, in which
- R.sub.1 denotes a hydrogen atom,
- R.sub.2 denotes an aminocarbonylamino group, which may be monosubstituted, disubstituted or trisubstituted by an alkyl group having 1 to 12 carbon atoms, by an alkenyl or alkynyl group each having 3 to 5 carbon atoms, by a bicyclic or tricyclic alkyl group having 7 to 11 carbon atoms, by a cycloalkyl, cycloalkylalkyl or phenylalkyl group, wherein the substituents may be the same or different, and the alkyl moiety may contain 1 to 3 carbon atoms and the cycloalkyl moiety may contain 5 to 7 carbon atoms, and an alkyl group may be substituted in the 4, 5 or 6 position by a hydroxy or trifluoroacetyl group,
- R.sub.3 denotes an alkyl group having 3 to 5 carbon atoms, an alkenyl or alkynyl group each having 3 to 5 carbon atoms,
- R.sub.4 denotes a carboxy or tetrazolyl group,
- R.sub.5 denotes a hydrogen atom, and
- R.sub.6 denotes a hydrogen atom.
- 5. A compound of the formula I according to claim 1, in which
- R.sub.1 denotes a hydrogen atom,
- R.sub.1 denotes an aminocarbonylamino group, which may be monosubstituted, disubstituted or trisubstituted by an alkyl group having 1 to 8 carbon atoms, by an alkenyl or alkynyl group each having 3 to 5 carbon atoms, by a bicyclic or tricyclic alkyl group having 7 to 11 carbon atoms, by a cycloalkyl, cycloalkylalkyl or phenylalkyl group, wherein the substituents may be the same or different, and the alkyl moiety may contain 1 to 3 carbon atoms and the cycloalkyl moiety may contain 5 to 7 carbon atoms, and an alkyl group may be substituted in the 4, 5 or 6 position by a hydroxy or trifluoroacetyl group,
- R.sub.3 denotes an alkyl group having 3 to 5 carbon atoms, an alkenyl or alkynyl group each having 3 to 5 carbon atoms,
- R.sub.4 denotes a carboxy or tetrazolyl group,
- R.sub.5 denotes a hydrogen atom, and
- R.sub.6 denotes a hydrogen atom.
- 6. A compound of the formula I according to claim 1, selected from the group consisting of the following:
- 4'-[(2-n-butyl-6-(N-(n-hexylaminocarbonyl)-benzylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-n-butylamino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-ethylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-n-propylamino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-methylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-cyclohexylaminocarbonylamino-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-n-pentylamino)-benzimidazol-1 -yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-methylaminocarbonyl-benzylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-benzylamino)-benz-imidazol-1 -yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(n-butylaminocarbonylamino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- ' -[(2-n-butyl-6-(N-(dimethylaminocarbonyl)-amino)-benzimida-zol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-n-hexylamino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-(5-hydroxy-n-pentylaminocarbonyl)-amino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-methylaminocarbonyl-n-pentylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-(n-butylaminocarbonyl)-methylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-(dimethylaminocarbonyl)-benzylamino)-benz-imidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-(N-(n-hexylaminocarbonyl)-N-(2-phenyl-ethyl)-amino)-benzimidazol-1-yl)-methyl]biphenyl-2-carboxylic acid,
- 4'-[(2-n-butyl-6-cyclohexylaminocarbonylamino-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl,
- 4'-[(2-n-butyl-6-dimethylaminocarbonylamino-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl,
- 4'-[(2-n-butyl-6-(N-cyclohexylaminocarbonyl-methylamino)-benzimidazol-1-yl)-methyl]-2-(1H-tetrazol-5-yl)-biphenyl,
- and pharmaceutically acceptable salts thereof.
- 7. A pharmaceutical composition comprising an angiotensin II antagonizing amount of a compound according to claims 1, 2, 3, 4, 5, or 6.
- 8. A method for treating hypertension which comprises administering to a subject suffering from hypertension an antihypertensive amount of a compound according to claims 1, 2, 3, 4, 5 or 6.
Priority Claims (2)
Number |
Date |
Country |
Kind |
39 11 603.4 |
Apr 1989 |
DEX |
|
39 28 177.9 |
Aug 1989 |
DEX |
|
Parent Case Info
This is a continuation of application Ser. No. 979,400, filed Nov. 19, 1992, now abandoned which is a continuation of application Ser. No. 750,175, filed Aug. 26, 1991, now abandoned, which is a continuation of application Ser. No. 505,967, filed Apr. 6,1990, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4880804 |
Carini et al. |
Nov 1989 |
|
Foreign Referenced Citations (4)
Number |
Date |
Country |
0132606 |
Feb 1985 |
DEX |
0142754 |
May 1985 |
DEX |
0253310 |
Jan 1988 |
DEX |
0291969 |
Nov 1988 |
DEX |
Continuations (3)
|
Number |
Date |
Country |
Parent |
979400 |
Nov 1992 |
|
Parent |
750175 |
Aug 1991 |
|
Parent |
505967 |
Apr 1990 |
|